Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQ05105 in steroid-refractory/dependent moderate to severe chronic GVHD
CTR20233240Phase 2Terminated
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rovadicitinib in chronic graft-versus-host disease (cGVHD), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Oct 2023; status: terminated.
02
Drugs
rovadicitinib
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on CTR20233240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233240.